Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 2, 2022

Primary Completion Date

March 21, 2024

Study Completion Date

November 13, 2024

Conditions

NSCLCEGFR Activating MutationBrain MetastasesLeptomeningeal Metastasis

Interventions

DRUG

TY-9591 Tablets

TY-9591 Tablets 160mg/d

Trial Locations (1)

National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors

lead

TYK Medicines, Inc

INDUSTRY